Company news
Mangoceuticals, Inc. news in 2026
Mangoceuticals, Inc.'s news releases, calls and decks from 2026, newest first.
Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close
October 9, 2026
Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
October 1, 2026
Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets
August 13, 2026
Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
August 5, 2026
Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
August 4, 2026
Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology
July 30, 2026
Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
March 16, 2026
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
March 5, 2026
Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
February 23, 2026
MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
February 19, 2026